EUVIMEDOpdag EUVIMED
Übersichtsarbeit

Effects of metformin on cancers in experimental and clinical studies: Focusing on autophagy and AMPK/mTOR signaling pathways

Mohammad Yasin Zamanian, Maryam Golmohammadi, Alexey Yumashev, Ahmed Hjazi, Mariam Alaa Toama, Mervat Ahmed AbdRabou, Anita Gehlot, Enas R Alwaily, Niyousha Shirsalimi, Pankaj Kumar Yadav, Gervason Moriasi

Cell Biochemistry and Function · 2024-06 · 42 (4)

DOI: 10.1002/cbf.4071 ↗

At a glance

Übersichtsarbeit in Cell Biochemistry and Function, published online on 2024-06-11. Written by Mohammad Yasin Zamanian and 10 co-authors. Institution: Department of Physiology, School of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran. Major MEDLINE topics: Metformin, Autophagy, TOR Serine-Threonine Kinases, Signal Transduction. Cited 51 times so far (Crossref); 185 references.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Metformin (MET) is a preferred drug for the treatment of type 2 diabetes mellitus. Recent studies show that apart from its blood glucose‐lowering effects, it also inhibits the development of various tumours, by inducing autophagy. Various studies have confirmed the inhibitory effects of MET on cancer cell lines’ propagation, migration, and invasion. The objective of the study was to comprehensively review the potential of MET as an anticancer agent, particularly focusing on its ability to induce autophagy and inhibit the development and progression of various tumors. The study aimed to explore the inhibitory effects of MET on cancer cell proliferation, migration, and invasion, and its impact on key signaling pathways such as adenosine monophosphate‐activated protein kinase (AMPK), mammalian target of rapamycin (mTOR), and PI3K. This review noted that MET exerts its anticancer effects by regulating key signalling pathways such as phosphoinositide 3‐kinase (PI3K), LC3‐I and LC3‐II, Beclin‐1, p53, and the autophagy‐related gene (ATG), inhibiting the mTOR protein, downregulating the expression of p62/SQSTM1, and blockage of the cell cycle at the G0/G1. Moreover, MET can stimulate autophagy through pathways associated with the 5′ AMPK, thereby inhibiting he development and progression of various human cancers, including hepatocellular carcinoma, prostate cancer, pancreatic cancer, osteosarcoma, myeloma, and non‐small cell lung cancer. In summary, this detailed review provides a framework for further investigations that may appraise the autophagy‐induced anticancer potential of MET and its repurposing for cancer treatment.

Subjects

MeSH terms (MEDLINE)

MetforminAutophagyTOR Serine-Threonine KinasesSignal TransductionNeoplasmsAMP-Activated Protein KinasesHumansAntineoplastic AgentsAnimals

Author keywords

AMPKautophagyautophagy markerscancermTOR pathwaymetformin

Substances

MetforminTOR Serine-Threonine KinasesAMP-Activated Protein KinasesMTOR protein, humanAntineoplastic Agents

Authors and institutions

  • Department of Physiology, School of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran.
  • Department of Pharmacology and Toxicology, School of Pharmacy, Hamadan University of Medical Sciences, Hamadan, Iran.
  • School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
  • Department of Prosthetic Dentistry, Sechenov First Moscow State Medical University, Moscow, Russian Federation.
  • Department of Medical Laboratory Sciences, College of Applied Medical Sciences, Prince Sattam bin Abdulaziz University, Al-Kharj, Saudi Arabia.
  • College of Pharmacy, National University of Science and Technology, Dhi Qar, Iraq.

Cite

APA

Zamanian, M. Y., Golmohammadi, M., Yumashev, A., Hjazi, A., Toama, M. A., AbdRabou, M. A., Gehlot, A., Alwaily, E. R., Shirsalimi, N., Yadav, P. K., & Moriasi, G. (2024). Effects of metformin on cancers in experimental and clinical studies: Focusing on autophagy and AMPK/mTOR signaling pathways. Cell Biochemistry and Function, 42(4). https://doi.org/10.1002/cbf.4071

Vancouver

Zamanian MY, Golmohammadi M, Yumashev A, Hjazi A, Toama MA, AbdRabou MA, et al. Effects of metformin on cancers in experimental and clinical studies: Focusing on autophagy and AMPK/mTOR signaling pathways. Cell Biochemistry and Function. 2024;42(4). doi:10.1002/cbf.4071

BibTeX
@article{Zamanian2024,
  author = {Zamanian, Mohammad Yasin and Golmohammadi, Maryam and Yumashev, Alexey and Hjazi, Ahmed and Toama, Mariam Alaa and AbdRabou, Mervat Ahmed and Gehlot, Anita and Alwaily, Enas R and Shirsalimi, Niyousha and Yadav, Pankaj Kumar and Moriasi, Gervason},
  title = {Effects of metformin on cancers in experimental and clinical studies: Focusing on autophagy and AMPK/mTOR signaling pathways},
  journal = {Cell Biochemistry and Function},
  year = {2024},
  volume = {42},
  number = {4},
  doi = {10.1002/cbf.4071}
}
Start for free →